Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.50
Bid: 1,604.00
Ask: 1,604.50
Change: 4.50 (0.28%)
Spread: 0.50 (0.031%)
Open: 1,600.50
High: 1,612.50
Low: 1,591.00
Prev. Close: 1,595.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 100 movers: GSK and Hikma lead blue chips higher

Wed, 29th Jul 2015 15:24

(ShareCast News) - The FTSE 100 index built an early lead on Wednesday and stayed in positive territory thanks to forecast-busting results from several heavyweights in the pharma, tobacco and banking sectors.London's blue chip index was up 0.57% to 6,592.54 at 1435 BST.Top of the leaderboard mid-afternoon were a pair of drug companies. GlaxoSmithKline's shares rallied after the big pharma company posted better-than-expected earnings and operating profits for the second quarter, and said it expected to see a significant recovery in core earnings per share next year.Sector peers Hikma Pharmaceuticals was given a shot in the arm by an upgraded recommendation from Jefferies. The broker raised its price target to 2,615p from 2,134p as it made references to lyrics in The Police's hit song and integrated the company's "transformational" deal with Roxane Laboratories, saying it gave the "green light" for a 'buy' rating.In another defensive sector, British American Tobacco posted a rise in first-half profit, although revenue for the period was dented by currency moves. Nevertheless, the big tobacco player, which owns Dunhill and Lucky Stripe, said net profit for the year to 30 June came in at £2.65bn, up from £1.75bn and better than consensus expectations for £2.44bn.Sector peer Imperial Tobacco was also lifted by the news.Barclays moved higher as its first half results beat forecasts, with an 11% increase in adjusted pre-tax profits as it set aside a further £1.6bn provision for further litigation and mis-selling after paying the same amount in the period. Executive chairman John McFarlane highlighted his pleasure at recent progress in the investment bank and called for the "need to accelerate the execution" of strategy.Leading the fallers was catering group Compass, after it warned of plans to restructure is fast growing and emerging (FG&E) markets business. Although third quarter results were mostly in line with forecasts, the costs of this rejig would impact full year operating margins.Shares in outsourcing group Capita also fell in spite of its announcement of an 11% rise in underlying first-half pre-tax profit, with most of it divisions performed well. However, this was undermined by the admission that the second half likely to be softer as the company said it only expected a "slight acceleration" in organic growth due do some delays.And Sky was another faller against a backdrop of solid results. Full-year numbers from the satellite broadcaster were better than the market expected in many places, thanks to impressive UK pay TV and broadband subscription levels. Investec noted that flagged profit growth was not as fast as it had been after nine months due to tougher comparatives and investment. FTSE 100 - RisersGlaxoSmithKline (GSK) 1,375.00p +3.50%Hikma Pharmaceuticals (HIK) 2,402.00p +3.49%British American Tobacco (BATS) 3,659.00p +3.03%Vodafone Group (VOD) 240.30p +2.06%Barclays (BARC) 285.35p +2.06%Imperial Tobacco Group (IMT) 3,346.00p +1.83%Relx plc (REL) 1,090.00p +1.49%ARM Holdings (ARM) 1,001.00p +1.42%Carnival (CCL) 3,405.00p +1.31%Experian (EXPN) 1,170.00p +1.30%FTSE 100 - FallersCompass Group (CPG) 1,033.00p -4.88%Antofagasta (ANTO) 571.50p -2.47%Capita (CPI) 1,261.00p -1.94%Smiths Group (SMIN) 1,119.00p -1.84%Admiral Group (ADM) 1,480.00p -1.07%Sky (SKY) 1,112.00p -1.07%Glencore (GLEN) 210.45p -0.99%RSA Insurance Group (RSA) 513.50p -0.96%Sage Group (SGE) 515.00p -0.96%International Consolidated Airlines Group SA (CDI) (IAG) 551.00p -0.90%
More News
26 Jun 2024 22:50

US CDC narrows age recommendation for RSV shots in US

June 26 (Reuters) - The U.S. CDC on Wednesday narrowed its recommendation for use of respiratory syncytial virus vaccines in older adults this year and held off on recommending their use for adults under age 60.

Read more
26 Jun 2024 11:00

US advisers to consider RSV shots as GSK looks to keep market lead

June 26 (Reuters) - A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles rival Pfizer and new entrant Moderna to keep its top position in the market.

Read more
25 Jun 2024 08:25

Merck KGaA shares plunge after cancer drug hopeful fails

FRANKFURT, June 25 (Reuters) - Shares in Germany's Merck KGaA slumped 8.9% at the open on Tuesday after the diversified group late on Monday said a trial testing a head and neck cancer drug, previously seen as promising, would be stopped for lack of efficacy.

Read more
24 Jun 2024 08:55

TOP NEWS: GSK hails Omjjara approval in Japan; Jemperli review in EU

(Alliance News) - GSK PLC on Monday said it has landed an approval in Japan and also highlighted regulatory progress in the EU.

Read more
24 Jun 2024 07:43

LONDON BRIEFING: Prudential announces buyback; Frasers and THG in deal

(Alliance News) - London's FTSE 100 is called to open lower at the start of the week, with share price falls for major US tech shares, Nvidia included, spooking investors on this side of the Atlantic.

Read more
24 Jun 2024 07:21

GSK reports regulatory progress for Omjjara, Jemperli

(Sharecast News) - GSK announced on Monday that it has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for 'Omjjara', or momelotinib, as a treatment for myelofibrosis.

Read more
20 Jun 2024 16:01

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.

Read more
11 Jun 2024 14:31

Zantac litigation fears overdone at GSK, says Shore Capital

(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but the long-term investment case is "still appealing", according to Shore Capital, which kept a 'buy' rating on the stock.

Read more
11 Jun 2024 09:32

TOP NEWS: GSK takes first steps to appeal Zantac ruling in Delaware

(Alliance News) - GSK PLC on Tuesday said it has taken the first steps to seek appeal of a ruling by the Delaware Superior Court in regard to its discontinued heartburn drug Zantac.

Read more
11 Jun 2024 09:12

LONDON MARKET OPEN: FTSE 100 up; UK unemployment rises to 4.4%

(Alliance News) - Stock prices in London opened higher on Tuesday, after a difficult day for markets on Monday amid the EU election fallout.

Read more
11 Jun 2024 07:52

LONDON BRIEFING: FTSE 100 called up despite unemployment rise

(Alliance News) - The FTSE 100 in London was called to open higher on Tuesday, after data showed that unemployment in the UK unexpectedly rose.

Read more
11 Jun 2024 07:22

GSK launches appeal to recent Zantac ruling

(Sharecast News) - GSK has started the process of appealing a recent decision by the Delaware Superior Court regarding the ongoing Zantac, or ranitidine, litigation, it announced on Tuesday.

Read more
11 Jun 2024 00:32

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

June 10 (Reuters) -

Read more
10 Jun 2024 22:49

Latest trial over Zantac cancer claims called off as plaintiff drops case

June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced.

Read more
10 Jun 2024 19:00

TOP NEWS: GSK welcomes dismissal of Zantac case in Illinois

(Alliance News) - GSK PLC on Monday welcomed the dismissal of a case in the US concerning the heartburn drug, Zantac, which was due to start on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.